Journal
SCIENTIFIC REPORTS
Volume 2, Issue -, Pages -Publisher
NATURE PORTFOLIO
DOI: 10.1038/srep00667
Keywords
-
Categories
Funding
- NIH [R24 GM078233]
- Department of Veterans Affairs Senior Research Scientist Award
- Amgen
- Bristol-Myers Squibb
- CeNeRx
- Corcept
- GlaxoSmithKline
- Johnson Johnson
- Lundbeck
- Merck
- Organon
- Pfizer
- Sepracor
- Wyeth
- Rules Based Medicine
- Eisai
- Abbott
Ask authors/readers for more resources
Targeted metabolomics provides an approach to quantify metabolites involved in specific molecular pathways. We applied an electrochemistry-based, targeted metabolomics platform to define changes in tryptophan, tyrosine, purine and related pathways in the depressed and remitted phases of major depressive disorder (MDD). Biochemical profiles in the cerebrospinal fluid of unmedicated depressed (n=14; dMDD) or remitted MDD subjects (n=14; rMDD) were compared against those in healthy controls (n=18; HC). The rMDD group showed differences in tryptophan and tyrosine metabolism relative to the other groups. The rMDD group also had higher methionine levels and larger methionine-to-glutathione ratios than the other groups, implicating methylation and oxidative stress pathways. The dMDD sample showed nonsignificant differences in the same direction in several of the metabolic branches assessed. The reductions in metabolites associated with tryptophan and tyrosine pathways in rMDD may relate to the vulnerability this population shows for developing depressive symptoms under tryptophan or catecholamine depletion.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available